This executive order aims to lower drug prices by prioritizing American manufacturing and reducing the influence of foreign competition, while also promoting transparency in pharmaceutical pricing practices. By addressing these issues, the order hopes to provide relief for Americans who have struggled with rising healthcare costs due to expensive prescription medications. Additionally, by encouraging the development of generics and biosimilars, the order seeks to increase competition in the market and drive down prices further. Overall, this executive order is a positive step towards improving access to affordable healthcare for all Americans.
Read the full text of the order at the whitehouse.gov website.